Ohio State Navbar

News


James S. Blachly, MD, One of six receipients of a Young Investigator Award


May 05, 2015

James S. Blachly, MD, assistant professor in the Division of Hematology at Ohio State and member of the Leukemia Research Program at the OSUCCC – James, is one of six recipients of a Young Investigator Award from the National Comprehensive Cancer Network (NCCN) Foundation®. His grant is for $150,000 over two years for a project titled “Genomic Stratification and Prognostication of Adult Acute Myeloid Leukemia by Combination Mutation Status.” Blachly’s co-mentors for the award are Clara D. Bloomfield, MD, a Distinguished University Professor who also serves as OSU cancer scholar and senior adviser to the OSUCCC – James, and John C. Byrd, MD, director of the Division of Hematology and co-leader of the Leukemia Research Program. The rest of the story



OSU Researchers Contribute to ASCO's Choice for 'Cancer Advance of the Year'


March 31, 2015

OSU Researchers Contribute to ASCO’s Choice for ‘Cancer Advance of the Year’ Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) scientists played a key role in some of the recent research that has helped transform treatment for chronic lymphocytic leukemia (CLL)—a transformation that the American Society of Clinical Oncology (ASCO) calls the “Cancer Advance of the Year.” ASCO’s Clinical Cancer Advances 2015 notes that four new therapies, including two targeted drugs and two immunotherapies, have been approved by the FDA in just a year’s time for CLL, the most common form of adult leukemia. Much of the research leading to approval of the drug ibrutinib, one of the two targeted agents, was performed by scientists at the OSUCCC – James. The rest of the story



Researchers Detail Reasons for Ibrutinib Therapy Discontinuation in CLL


March 31, 2015

About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical trials, according to a study at the OSUCCC – James that was published in JAMA Oncology. Kami Maddocks,MD, of the Division of Hematology at Ohio State, was first author on the study, and Jennifer Woyach, MD, also of the Division of Hematology and a member of the Leukemia Research Program at the OSUCCC – James, was senior author. The rest of the story



Long Noncoding RNAs: A Novel Prognostic Marker in Older Patients With AML


March 31, 2015

A study led by researchers at the OSUCCC – James describes a novel marker that might help doctors choose the least toxic, most effective treatment for many older patients with acute myeloid leukemia (AML). AML occurs mainly in older patients and has a three-year survival rate of 5 to 15 percent. The study is published online in the Proceedings of the National Academy of Sciences. Clara D. Bloomfield, MD, a Distinguished University Professor who also serves as OSU cancer scholar and senior adviser to the OSUCCC – James, was principal investigator. Ramiro Garzon, MD, associate professor of internal medicine at Ohio State and member of the Leukemia Research Program at the OSUCCC – James, was first author. The rest of the story



BMT Nurses Win National Award for Patient Care Excellence


March 31, 2015

Nurses with the Blood and Marrow Transplant (BMT) Program at the OSUCCC – James have received national recognition for exceptional patient care and professional nursing practice with a three-year, bronze level Beacon Award for Excellence™ from the American Association of Critical-Care Nurses (AACN). The OSUCCC – James is the first BMT unit in the country to earn Beacon Award for Excellence recognition. The team includes 75 nurses. The rest of the story



$1.59 Million Grant Awarded


March 31, 2015

A team led by PIs Michael A. Caligiuri, MD, and Jianhua Yu, PhD, will use a five-year, $1.59 million grant to study how a dietary component from edible plants enhances the immune system’s ability to prevent AML or its recurrence. Caligiuri is director of the OSUCCC and CEO of The James. Yu is an assistant professor in the Division of Hematology and a member of the MCC Program. This project is a collaboration with co-investigator A. Douglas Kinghorn, PhD, DSc, a professor in the College of Pharmacy at Ohio State and member of the MCC Program. The rest of the story



STATE'S 2015 ASH REVIEW SLATED FOR JAN. 30


January 09, 2015

STATE'S 2015 ASH REVIEW SLATED FOR JAN. 30 The rest of the story



NEW JAMES OPEN FOR BUSINESS AND RUNNING SMOOTHLY


January 09, 2015

NEW JAMES OPEN FOR BUSINESS AND RUNNING SMOOTHLY The rest of the story



An Up-and-Coming Superstar!


November 04, 2014

Ashley Rosko, MD, an assistant professor in the Division of Hematology at Ohio State and a member of the Cancer Control Program at the OSUCCC – James, has received one of five Young Investigator Awards presented by the National Comprehensive Cancer Network (NCCN) Foundation. The Foundation annually awards these grants – each worth $150,000 over two years – to young investigators at NCCN member institutions who are dedicated to advancing and discovering treatments for cancer, enhancing quality and improving education. The awardees submitted grant proposals that were reviewed by a multidisciplinary panel of oncology experts who judged them on several components, including scientific merit and study design. Dr. Rosko’s funded project is “NCCN Senior Adult Oncology: Myeloma Comprehensive Geriatric Assessment and Biomarkers of Aging Investigation.” The OSUCCC – James is a charter member of the NCCN, a not-for-profit alliance of 25 of the world’s leading cancer centers. The alliance is dedicated to improving the quality and effectiveness of care provided to patients with cancer. The rest of the story



Health Care Heroes Recognized - John C. Byrd, Honorable Mention


July 17, 2014

Columbus Business First recognized the honorees for its Health Care Heroes Awards during an event Thursday morning. The rest of the story



Next